United Therapeutics (NASDAQ:UTHR) Price Target Raised to $400.00

United Therapeutics (NASDAQ:UTHR) had its price objective increased by Argus from $360.00 to $400.00 in a research note published on Thursday, Benzinga reports. Argus currently has a buy rating on the biotechnology company’s stock.

UTHR has been the subject of a number of other reports. Morgan Stanley downgraded shares of United Therapeutics from an “overweight” rating to an “equal weight” rating and boosted their target price for the company from $310.00 to $321.00 in a research report on Thursday, July 11th. StockNews.com raised shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, October 17th. Oppenheimer boosted their price objective on United Therapeutics from $400.00 to $575.00 and gave the company an “outperform” rating in a report on Wednesday, August 28th. LADENBURG THALM/SH SH downgraded United Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 1st. Finally, Jefferies Financial Group raised their price objective on United Therapeutics from $315.00 to $432.00 and gave the stock a “buy” rating in a report on Monday, September 23rd. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, United Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $370.86.

United Therapeutics Stock Performance

United Therapeutics stock opened at $374.02 on Thursday. United Therapeutics has a fifty-two week low of $208.62 and a fifty-two week high of $377.92. The company has a 50 day moving average price of $355.40 and a 200-day moving average price of $317.24. The company has a market capitalization of $16.70 billion, a PE ratio of 16.43, a P/E/G ratio of 1.35 and a beta of 0.56.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 EPS for the quarter, beating analysts’ consensus estimates of $6.16 by $0.23. The company had revenue of $748.90 million during the quarter, compared to analysts’ expectations of $722.62 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. United Therapeutics’s revenue for the quarter was up 22.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted $5.38 earnings per share. On average, analysts forecast that United Therapeutics will post 24.85 earnings per share for the current year.

Insiders Place Their Bets

In other news, CEO Martine A. Rothblatt sold 3,600 shares of the firm’s stock in a transaction on Tuesday, August 6th. The stock was sold at an average price of $325.45, for a total value of $1,171,620.00. Following the completion of the transaction, the chief executive officer now owns 130 shares in the company, valued at $42,308.50. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In related news, CEO Martine A. Rothblatt sold 3,600 shares of the business’s stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $325.45, for a total value of $1,171,620.00. Following the completion of the transaction, the chief executive officer now owns 130 shares of the company’s stock, valued at approximately $42,308.50. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, COO Michael Benkowitz sold 25,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $323.38, for a total transaction of $8,084,500.00. Following the sale, the chief operating officer now owns 2,577 shares in the company, valued at approximately $833,350.26. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 98,412 shares of company stock worth $33,971,508. Corporate insiders own 11.90% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of UTHR. Renaissance Technologies LLC increased its stake in United Therapeutics by 1.1% during the 2nd quarter. Renaissance Technologies LLC now owns 2,174,692 shares of the biotechnology company’s stock worth $692,748,000 after buying an additional 22,978 shares during the period. LSV Asset Management lifted its stake in United Therapeutics by 82.5% in the second quarter. LSV Asset Management now owns 966,370 shares of the biotechnology company’s stock valued at $307,837,000 after buying an additional 436,851 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in United Therapeutics by 4.0% during the 2nd quarter. Dimensional Fund Advisors LP now owns 585,969 shares of the biotechnology company’s stock valued at $186,656,000 after purchasing an additional 22,683 shares during the period. Pacer Advisors Inc. boosted its position in shares of United Therapeutics by 19.6% during the second quarter. Pacer Advisors Inc. now owns 561,834 shares of the biotechnology company’s stock worth $178,972,000 after buying an additional 92,240 shares during the period. Finally, Swedbank AB bought a new position in shares of United Therapeutics in the first quarter worth $97,316,000. 94.08% of the stock is owned by institutional investors and hedge funds.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.